Sun Pharmaceutical Industries Ltd. closed 10.67% short of its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Sun Pharmaceutical Industries Ltd. closed 13.65% short of its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

Sun Pharma declined 0.93 per cent to Rs 1,689.35. About10 per cent of the Sun Pharma's US specialty revenues is formulated in ...

Aurobindo Pharma and Gland Pharma have fallen 6-10 per cent each in the past one week and 20-23 per cent in 2025 so far.

The rise in the Sun Pharma share price came after a favourable ruling from a US court regarding its planned launch of ...

Emkay Global maintains a 'Buy' rating on Sun Pharma after the US Court of Appeals vacates the injunction against Leqselvi's ...

Sun Pharmaceuticals is one of India’s largest pharmaceutical companies with over 8% share in the domestic market. It owns 35 ...

The pharma sector is likely to maintain steady earnings. Most brokerages flag US business recovery as the key swing factor ...

On Thursday, April 10, Sun Pharma announced that the U.S. Court of Appeals for the Federal Circuit has vacated a preliminary ...

Nifty Pharma index sinks over 2% as Indian drugmakers face tariff heat; Gland, Aurobindo, Biocon, Sun Pharma among top losers ...